个人简历
刘小伟，博士，硕士生导师，四川大学华西医院乳腺健康医学研究院副研究员。2019年6月毕业于四川大学生物治疗国家重点实验室获生物化学与分子生物学博士；2019年9月-2022年12月于四川大学华西医院从事临床医学专职博士后工作；2023年1月起至今，四川大学华西医院乳腺健康医学研究院。
学术任职
中华医学会乳腺肿瘤分会青年委员；
四川省国际医学交流促进会人工智能与肿瘤专业委员会委员；
中国抗癌协会会员；
中国细胞生物学会会员；
担任Journal of the American Chemical Society (JACS)，MedComm，Clinical and Experimental Immunology等知名杂志审稿人；
科研、学术成果
长期聚焦胰腺癌、乳腺癌、黑色素瘤、结直肠癌等恶性肿瘤临床治疗的重大需求，开展以下两方面的基础与转化研究：1）利用多维基因组学结合功能基因组学研究肿瘤发生发展和免疫逃逸机制，筛选新的治疗靶点；2）开展以分子靶向、免疫治疗和纳米技术为核心的肿瘤精准治疗。围绕这一热点领域，开展了系统的研究，形成了特色的研究体系。近5年以通讯作者或第一作者在Cancer Cell（封面文章，ESI高被引论文）、Cell Discovery、Cell Reports Medicine、Advanced Functional Material（封面文章）、Journal of Controlled Release、Journal of Investigative Dermatology、Seminars in Cancer Biology（ESI高被引论文）、Frontiers in Immunology等杂志发表高水平论文20余篇，单篇最高影响因子50.6。相关成果申请国家发明专利4项。承担国家自然科学基金、国家博士后科学基金特别资助/面上项目、四川省科技计划重点研发项目、“十四五”国家重点研发计划等国家和省部级项目6项。曾获第十二届棒棰岛肿瘤前沿论坛青年创新一等奖、川渝科技学术大会优秀论文一等奖和二等奖各一次、四川省医学会2020年度优秀论文一等奖等奖励。
近五年，部分代表性论著：
- Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance, Cancer Cell, 2023, 41: 1-16 (封面文章，IF=50.6)
- Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance, Cell Discovery, 2024 Feb 9;10(1):16. (IF=33.5)
- MAPK-Targeted Drug Delivered by a pH-Sensitive MSNP Nanocarrier Synergizes with PD-1 Blockade in Melanoma without T-Cell Suppression, Advanced Functional Materials, 2019, 29(12): 1-16 (封面文章，IF=19)
- Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade, Journal of Controlled Release, 2021, 332: 194-209 (IF=10.8)
- PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer, Cell Reports Medicine, 2022, 9: 100741-100741 (IF=14.3)
- Artificial intelligence based multi-omics analysis fuels cancer precision medicine, Seminars in Cancer Biology, 2022, 88: 187-200 (IF=14.5)
- Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor resistant melanoma., Frontiers in Pharmacology, 2022, 13: 928226-928226 (IF=5.6)
- The Evolution of Acquired Resistance to BRAFV600E kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling, Journal of Investigative Dermatology, 2022, 142: 445-458 (IF=6.5)
- Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer, Frontiers in Immunology, 2022, 13 (IF=7.3)
- Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy, Frontiers in Immunology, 2022, 13 (IF=7.3)
A Novel Strategy to Fuel Cancer Immunotherapy: Targeting Glucose Metabolism to Remodel the Tumor Microenvironment, Prime Archives in Cancer Research, (Book chapter)